Today in Science
Abbott Laboratories isn’t making a bid for St. Jude Medical Inc., spokesman Scott Stoffel said.
Global sea levels are rising faster than predicted as a result of warming temperatures driven by burning fossil fuels, according to researchers who now say an increase of at least 3 feet (1 meter) is likely “unavoidable.”
China’s stocks slumped to a two-week low as concern a slowing economy and weaker currency will spur capital outflows outweighed prospects for more state support.
ARPA-E is trying to shake up the 100-year-old U.S. energy system
China’s fossil-fuel emissions are lower than than previously estimated, according to research led by academics at Harvard University.
The New Space Race
Bloomberg's Ed Hammond breaks down the busy summer M&A market on "Bloomberg Markets." (Source: Bloomberg)
Mylan NV’s shareholders voted in favor of moving forward with a $33 billion hostile bid for over-the-counter drugmaker Perrigo Co., putting the fate of the deal in Perrigo investors’ hands.
Amgen Inc. won U.S. approval for its powerful cholesterol-lowering drug Repatha for certain patients, making it the second in a new class of treatments to come to market.
A health plan for retired autoworkers is a surprising success
Aflac Inc. said Michael Tomlinson is stepping down as director of U.S. sales to focus on his health, less than a year after taking the role.